Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2

International Journal of Cancer

Volumn 116, Issue 3, 2005, Pages 359-367

  Longva, Karianne E ^a   Pedersen, Nina Marie ^a   Haslekås, Camilla ^a   Stang, Espen ^a   Madshus, Inger H ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Akt; Endocytosis; Erbb2; Herceptin; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; TRASTUZUMAB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MEMBRANE; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SWINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; DOWN-REGULATION; ENDOCYTOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 22244453690     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21015     Document Type: Article

References (42)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37. Available from http://www. ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed& dopt=Citation&list_uids=11252954.
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000;19:3159-67. Available from http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation &list_uids=10880430.
3. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SS. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991;6(7):1189-94. Available fromhttp://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 1713661.
4. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001;3:785-92. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 11533657.
5. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-21. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_ uids=7538656.
6. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J 1996;15:2452-67. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=8665853.
7. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Embo J 1995;14(17):4267-75. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db= PubMed&dopt=Citation&list_uids=7556068.
8. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=12648469.
9. Fedi P, Pierce JH, di Fiore PP, Kraus MH. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994;14:492-500. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=8264617.
10. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/ c-erbB-3 chimera. Embo J 1994;13:2831-41l. Available from http:// www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 8026468.
11. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000;19:1647-56.
12. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20:3210-23. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list_uids= 10757805.
13. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 11850835.
14. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=12124352.
15. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999;9: 125-38. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10202134.
16. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, German C, Shepard HM. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 8102322.
17. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72. Available from http://www.ncbi. nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt= Citation&list_uids=2566907.
18. Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996;56:1457-65. Available from http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation &list_uids=8640840.
19. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72-82. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db= PubMed&dopt=Citation&list_uids=1688187.
20. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 12908564.
21. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70. Available from http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt= Citation&list_uids=10482195.
22. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001;61:4892-900. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 11406568.
23. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001;28:4-11. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db= PubMed&dopt=Citation&list_uids=11706390.
24. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14:2099-109. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation& list_uids=9160890.
25. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=11406546.
26. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 15324695.
27. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC Jr. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 2002;62:7264-72. Available from http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation& list_uids=12499268.
28. Glauert AM, Reid N. Fixation, dehydration and embedding of biological specimens. Amsterdam: North-Holland, 1974.
29. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list_ uids=6188586.
30. Tikhomirov O, Carpenter G. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem 2000;275:26625-31.
31. Sonnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J Cell Biol 2000; 149:901-14. Available from http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids= 10811830.
32. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996;271:5251-7. Available from http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt= Citation&list_uids=8617810.
33. Hommelgaard AM, Lerdrup M, Van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004;15:1557-67. Available from http://www.ncbi.nlm. nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation &list_uids=14742716.
34. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier F, Adelaide J, Margolis B, Birnbaum D. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/ HER2 receptor. Nat Cell Biol 2000;2:407-14. Available from http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed& dopt=Citation&list_uids=10878805.
35. Jaulin-Bastard F, Saito H, Le Bivic A, Ollendorff V, Marchetto S, Birnbaum D, Borg JP. The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins. J Biol Chem 2001;276:15256-63. Available from http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation &list_uids=11278603.
36. Shelly M, Mosesson Y, Citri A, Lavi S, Zwang Y, Melamed-Book N, Aroeti B, Yarden Y. Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Dev Cell 2003;5:475-86. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids= 12967566.
37. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. Mol Biol Cell 2004;15:5268-82. Available from http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=15385631.
38. Liu W, Li J, Roth RA. Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophys Res Commun 1999;261:897-903. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=10441522.
39. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003;22:2897-909. Available from http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list_ uids=12771940.
40. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999;96:1563-8. Available from http://www. ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed &dopt=Citation&list_uids=9990064.
41. Hung MC, Schlechter AL, Chevray PY, Stern DF, Weinberg RA. Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci U S A 1986;83:261-4. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db= PubMed&dopt=Citation&list_uids=3001730.
42. Hellyer NJ, Kim MS, Koland JG. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 2001;276:42153-61. Available from http://www.ncbi. nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list_uids=11546794.